This story was first published in digitalhealth.net
New drug for multiple sclerosis patients
Multiple sclerosis drug, Extavia, has been approved for routine funding on the NHS, in NICE draft guidance.
A discount to the price of this beta interferon drug means that it can be recommended as a cost effective option for adults with relapsing-remitting multiple sclerosis (MS) or secondary progressive MS with continued relapses.
Extavia is self-injected every two days and works by slowing down the damage to the nervous system caused by MS and by reducing the number of MS-related relapses. The committee noted evidence that suggested drugs of this type become less effective over the first two years.
As part of this appraisal NICE did not recommend MS drugs glatiramer acetate and the other beta interferons (Avonex, Betaferon, Plegridy and Rebif), as they were found to be not cost effective.
Extavia has a list price per patient per year of £7,259 however the discounted price that was approved remains confidential.
Carole Longson, director of the centre for health technology evaluation at NICE, said: “Multiple sclerosis is lifelong condition that can limit people’s ability to work, and to engage in social and family life. Being able to delay the progression of the disease is important to help patients get back to their normal lives.
“We are delighted that Novartis has been able to agree a reduction to the price of Extavia to allow it to be made routinely available to people with this type of multiple sclerosis.
"We are keen to work with the companies for the other drugs to ensure that patients continue to benefit from a choice in treatment for multiple sclerosis."
Latest News
16/02/2024 - 12:56
Hammersmith and Fulham Council has created a new alliance intended to clean dirty air and improve residents' health.
16/02/2024 - 10:44
Two million more GP appointments a month are being delivered for patients compared to the same month before the pandemic as part of the NHS primary care access recovery plan according to new NHS data.
15/02/2024 - 10:26
The Welsh Government has provided innovation funding of £380,000 to support two projects utilising technology in domiciliary care.
15/02/2024 - 10:13
The new Scottish health secretary has met with frontline staff at Queen Elizabeth University Hospital in Glasgow.
14/02/2024 - 10:27
The North East London NHS Foundation Trust (NELFT) has appointed three new Executive Directors to the Trust Board.
Product Features
UK Building Regulations highlight toxic gas and smoke from layers of paint built up over multiple redecorations as a major cause of permanent ill health or death in a building fire.
Their concern rose with discovery the flame retardant paints most widely used paint along escape routes have been ones which to this day counter-productively use emission of heavy toxic gas to smother flames which rapidly spread along walls if layers of paint delaminate in a fire.
Supplier Profiles
Northwich’s Victoria Infirmary (VIN) Community Diagnostic Centre (CDC) has enabled more patients
Adveco, the commercial hot water specialist, announces the launch of live metering of domestic ho
Latest Features
Sarah Greenslade, public affairs and communications officer at the British Parking Association looks at some of the problems and innovations in healthcare parking
It’s easy to assume that the comms team is there to handle press enquiries and the occasional social media storm – but the reality is that strategic communications can make a measurable impact across the entire organisation, from operational to financial, when done properly
